Valuation Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE
Stocks
PLX
US74365A3095
Pharmaceuticals
|
Delayed
TEL AVIV STOCK EXCHANGE
19:24:48 21/03/2023 +04
|
5-day change | 1st Jan Change | ||
| 732.50 ILa | -.--% |
|
+3.29% | +69.68% |
| 08-12 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 178.9 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 23.56% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 178.9 | 178.9 | 178.9 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 23.56% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.7x | 18.5x | 111x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.5x | -1.3x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.24x | 2.62x | 2.6x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.24x | 2.62x | 2.6x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.75x | 21.1x | 158x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.19 | 0.12 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 79.8 | 68.19 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 18.35 | 8.476 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.38 | 10.01 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.220 | 2.220 | 2.220 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/03/22 | 27/02/23 | 14/03/24 | 17/03/25 | 18/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.76x | 12.18x | 24.85x | 0.59% | 1,052B | |
| 28.96x | - | - | 2.06% | 627B | |
| 31.84x | 7.42x | 15.42x | 2.75% | 441B | |
| 19.79x | 4.7x | 11.65x | 2.81% | 349B | |
| 21.42x | 5.54x | 13.77x | 2.89% | 287B | |
| 19.89x | 4.11x | 11.68x | 2.14% | 241B | |
| 26.26x | 6.84x | 12.14x | 2.43% | 224B | |
| 13.32x | 4.79x | 9.96x | 3.83% | 202B | |
| -42.28x | 6.13x | 23.96x | 2.38% | 172B | |
| Average | 17.00x | 6.46x | 15.43x | 2.43% | 399.46B | |
| Weighted average by Cap. | 24.17x | 8.04x | 17.73x | 2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
